RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one
Main Authors: | Rodolfo P. Rothlin, Facundo Pelorosso, Mariano Duarte, Liliana Nicolosi, Ignacio Fernandez Criado, María Victoria Salgado, Héctor Vetulli |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Revista Portuguesa de Cardiologia |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0870255123004596 |
Similar Items
-
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
by: Rodolfo Pedro Rothlin, et al.
Published: (2023-04-01) -
Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one
by: Jorge Gonçalves, et al.
Published: (2024-04-01) -
Not all group incentives are created equally
by: Salk, C, et al.
Published: (2018) -
All Purkinje cells are not created equal
by: Catarina Albergaria, et al.
Published: (2014-06-01) -
When all information is not created equal
by: Borade, Shashibhushan Prataprao, 1981-
Published: (2009)